Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.
Looks like Edison are working on an update http://www.edisoninvestmentresearch.com/research/company/hutchison-china-meditech I suspect as will a few more analysts The pipeline is progressing well, with material clinical results due during the coming year, with potential for savolitinib's US NDA submission under breakthrough therapy designation by year end. We . Our forecasts are currently under review.